Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Finished Goods: 2023-2024

Historic Finished Goods for Zevra Therapeutics (ZVRA) over the last 1 years, with Sep 2024 value amounting to $1.1 million.

  • Zevra Therapeutics' Finished Goods was N/A to $1.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2023, which is N/A change from last year.
  • As of Q3 2024, Zevra Therapeutics' Finished Goods stood at $1.1 million, which was down 45.35% from $2.1 million recorded in Q2 2024.
  • In the past 5 years, Zevra Therapeutics' Finished Goods ranged from a high of $5.1 million in Q1 2024 and a low of $1.1 million during Q3 2024.
  • Its 2-year average for Finished Goods is $3.3 million, with a median of $3.5 million in 2023.